Parent Page: Academic Departments id: 22555 Active Page: Facultyid:23541


Amir Rumman, MD
Internal Medicine

Amir Rumman, MD

Assistant Professor of Medicine
Associate Director of Interventional Endoscopy

COMD 7400
800 Stanton L Young Blvd
Oklahoma City, OK


Amir Rumman, MD, FRCPC is an Assistant Professor of Medicine in the Section of Digestive Diseases and Nutrition, Department of Medicine, University of Oklahoma. Dr. Rumman maintains a comprehensive practice in interventional pancreatico-biliary and luminal endoscopy, and currently serves as the Associate Director of Interventional Endoscopy at the University of Oklahoma Health Sciences Center.

Dr. Rumman completed medical school at Queen’s University in Canada. He underwent residency training in internal medicine and fellowship training in gastroenterology at the University of Toronto. Additional training in interventional endoscopy was completed at the University of Virginia.

In addition to clinical work, Dr. Rumman is actively involved in research and education of medical students and trainees. His research focus is in health services and outcomes research and clinical epidemiological studies in interventional endoscopy.

Academic Section(s):

Digestive Diseases and Nutrition


MD, Queen’s University, Kingston, Canada
BSc Life Science, Queen’s University, Kingston, Canada

Board Certification(s):

American Board of Internal Medicine

Royal College of Physicians and Surgeons of Canada


Internal Medicine, University of Toronto, Toronto, Canada


Gastroenterology, University of Toronto, Toronto, Canada

Interventional Endoscopy, University of Virginia, Charlottesville, VA

Clinical/Research Interests:



Enteral stenting

Barrett esophagus therapy

Advanced polypectomy


Pancreatic cysts


Pancreatic cancer

Esophageal cancer


Select Publications:

Khan R, Habbal M, Scaffidi MA, Bukhari AA, Rumman A, Al Ghamdi S, Betschel SD, Grover SC.   Gastrointestinal Disease in Patients with Common Variable Immunodeficiency: A Retrospective Observational Study.  J Can Assoc Gastroenterol. 2020 Aug;3(4):162-168. doi: 10.1093/jcag/gwz004. Epub 2019 Feb 25. PMID: 32671325

Gallinger ZR, Rumman A, Pivovarov K, Fortinsky K, Dubinsky M, Grover SC, Cohen B, Nguyen GC.  Inflammatory Bowel Disease Training During Adult Gastroenterology Residency: A National Survey of Canadian Program Directors and Trainees.  J Can Assoc Gastroenterol. 2019 Aug;2(3):118-125. doi: 10.1093/jcag/gwy034. Epub 2018 Jul 31. PMID: 31294374

Habbal M, Scaffidi MA, Rumman A, Khan R, Ramaj M, Al-Mazroui A, Abunassar MJ, Jeyalingam T, Shetty A, Kandel GP, Streutker CJ, Grover SC.  Clinical, endoscopic, and histologic characteristics of lymphocytic esophagitis: a systematic review. Esophagus. 2019 Apr;16(2):123-132. doi:10.1007/s10388-018-0649‑1.  pub 2018 Oct 29. DOI: 10.1007/s10388-018-0649-1 PMID: 30370453

Grindal AW, Khan R, Scaffidi MA, Rumman A, Grover SC. Financial Conflicts of Interest in Inflammatory Bowel Disease Guidelines.   Inflamm Bowel Dis. 2019 Mar 14;25(4):642-645. doi: 10.1093/ibd/izy315. PMID: 30295831

Khan R, Scaffidi MA, Rumman A, Grindal AW, Plener IS, Grover SC.  Prevalence of Financial Conflicts of Interest Among Authors of Clinical Guidelines Related to High-Revenue Medications.   JAMA Intern Med. 2018 Dec 1;178(12):1712-1715. doi: 10.1001/jamainternmed.2018.5106.  PMID: 30383094

Gallinger ZR, Rumman A, Pivovarov K, Fortinsky KJ, Steinhart AH, Weizman AV.  Frequency and Variables Associated with Fasting Orders in Inpatients with Ulcerative Colitis: The Audit of Diet Orders-Ulcerative Colitis (ADORE-UC) Study. Inflamm Bowel Dis. 2017 Oct;23(10):1790-1795. doi:10.1097/ MIB.0000000000001244.  PMID: 28906293

Gallinger ZR, Rumman A, Murthy SK, Nguyen GC. Perspectives on endoscopic surveillance of dysplasia in inflammatory bowel disease: a survey of academic gastroenterologists.  Endosc Int Open. 2017 Oct;5(10):E974-E979. doi: 10.1055/s-0043-117944. Epub 2017 Oct 4. PMID: 28983504

Rumman A, Candia R, Sam JJ, Croitoru K, Silverberg MS, Steinhart AH, Nguyen GC.  Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease.  Can J Gastroenterol Hepatol. 2017;2017:7365937. doi: 10.1155/2017/7365937. Epub 2017 Jan 23. PMID: 28239601